1Department of Neurosciences, Apollo Speciality Hospitals, Lake View Road, KK Nagar, Madurai, Tamil Nadu 625020, India.
2Department of Cardiology, Apollo Speciality Hospitals, Lake View Road, KK Nagar, Madurai, Tamil Nadu 625020, India.
3Department of Emergency Services, Apollo Speciality Hospitals, Lake View Road, KK Nagar, Madurai, Tamil Nadu 625020, India.
Correspondence Address: Dr. Salvadeeswaran Meenakshi-Sundaram, Department of Neurosciences, Apollo Speciality Hospitals, Lake View Road, KK Nagar, Madurai, Tamil Nadu 625020, India. E-mail: firstname.lastname@example.org
Dr. Salvadeeswaran Meenakshi-Sundaram is a Senior Consultant and Associate Professor in the Department of Neurosciences, Apollo Speciality Hospitals, Madurai, India. He is the recipient of Gold Medal and was the Best Outgoing Student of the Year 2000, at National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore, India. He received the Best Research Paper Award at the 10th Annual Conference of Indian Academy of Neurology (IAN), Lucknow, India, 2002. He is actively involved in acute stroke-related work.
This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the identical terms.
The authors report the first case of thrombolysis in a patient already receiving both aspirin and prasugrel following a recent ischemic coronary event. A 55-year-old gentleman was treated for inferior wall myocardial infarction with aspirin, prasugrel and percutaneous angioplasty of right coronary artery. Three days following the procedure he developed acute ischemic stroke due to a left middle cerebral artery infarction with a National Institute of Health Stroke Scale (NIHSS) of 24 and was treated with alteplase. Therapy was interrupted after completion of 29 mg (for a body weight of 65 kg) dose due to oral bleeding. Fifteen minutes post thrombolysis NIHSS was 5 and dropped to zero after 12 h. This report highlights the benefits of alteplase in the context of several relative contraindications like the setting of acute myocardial infarction treated with percutaneous intervention and high NIHSS.
Intravenous thrombolysis, ischemic stroke, percutaneous coronary angioplasty, prasugrel
Intravenous thrombolysis is the standard of care in acute ischemic stroke, and is associated with significant improvement in outcome measures. Intracerebral hemorrhage is an absolute contraindication for thrombolysis. While due diligence must be exercised, strict interpretations of relative contraindications might prove a barrier to potentially life changing thrombolysis in stroke[2,3]. Hence decisions regarding thrombolysis are made on a case-by-case basis. We report a patient who, whilst on prasugrel and aspirin for post-myocardial infarction (MI), made a dramatic recovery from acute ischemic stroke after thrombolysis.
A 55-year-old gentleman was referred to our hospital two days following the development of inferior wall myocardial infarction (IWMI) diagnosed as ST-elevation myocardial infarction (STEMI) that had been treated with antiplatelets and statin. The last ECG at the time of discharge after the IWMI revealed evolved infarction. Three days after the onset of IWMI he underwent percutaneous angioplasty of the right coronary artery. Three days following this procedure, he was discharged on the following medications: aspirin 150 mg/day, prasugrel 10 mg/day, and atorvastatin 40 mg/day. While being discharged he developed weakness of right sided limbs, inability to comprehend or talk, and became drowsy. There was no history of headache, vomiting, or convulsions. At the emergency room, his vital parameters were: BP 110/60 mmHg, pulse 64/min. He had global aphasia, right gaze palsy, right hemiplegia, hemianopia, hemihypoaesthesia, and sensory inattention. National Institute of Health Stroke Scale (NIHSS) was 28. Blood sugar was 160 mg%. CT scan of the brain was unremarkable. MRI of the brain, done 30 min after the onset of stroke, revealed a moderate sized infarct involving the left middle cerebral artery territory [Figure 1A and B]. MR angiogram revealed diffuse pruning of M1 and significant reduction of signals in M2 and M3 segments [Figure 1C]. Echocardiogram revealed no intracardiac clot.
Figure 1. (A) is a diffusion weighted image showing diffusion restriction involving left gangliocapsular and perisylvian regions (shown by arrows) corresponding to left middle cerebral artery territory; (B) is the corresponding apparent diffusion coefficient map showing low signals in the left gangliocapsular region; (C) shows diffuse pruning of M1 and significant reduction of signals in M2 and M3 segments of the left middle cerebral artery (shown by arrows)
The risks and benefits of intravenous thrombolysis were discussed with the family. After obtaining informed consent alteplase was administered. Stroke-onset to needle-time was 55 min. Following the bolus of 5.5 mg, a mild improvement in motor power was noted when he could minimally move the right lower limb. There was a gradual improvement of limb power during the infusion of alteplase. He developed an oral bleed after 29 mg of the drug had been infused. Further infusion was discontinued. Limb power improved to grade 3/5 over the upper and lower limbs, and verbal comprehension was normal. However, he continued to have Broca’s aphasia. CT scan of the brain, done immediately, did not reveal intracerebral hemorrhage. No further administration of alteplase was done. Fifteen minutes post thrombolysis Broca’s aphasia also significantly improved and he could speak several words fluently. NIHSS was 5. Twelve hours post thrombolysis, NIHSS was zero. Repeat CT scan did not reveal any hemorrhagic complications. Aspirin, 150 mg/day, was started after 24 h and clopidogrel, 75 mg/day, after 48 h. He maintained improvement and was discharged 4 days after the onset of stroke.
Alteplase is the only approved intravenous thrombolytic therapy for stroke and is recommended in the first 4.5 h following the onset of acute ischemic stroke. Contraindications to its use were derived from the exclusion criteria utilized in major stroke trials, and violation of protocols have been shown to be associated with complications, importantly intracerebral hemorrhage. However, many of the contraindications have proven to be unnecessarily restrictive in real-world clinical practice, and patients have been thrombolysed off-label with consistent benefits[4,6]. Our patient had a recent myocardial infarction, traditionally considered as a contraindication for intravenous thrombolysis. Since the preferred option of mechanical thrombectomy is available only in a few select centers with such expertise, we opted for intravenous thrombolysis which has the inherent risks of myocardial rupture, pericardial hemorrhage and cardiac tamponade. Fortunately, these complications are less likely to occur with inferior wall myocardial infarction in contrast to anterior, and patients have undergone thrombolysis in this situation with benefits. Also, we did not consider the percutaneous intervention, done 3 days prior, as a specific contraindication for therapy. Traditionally, an NIHSS of more than 20 or 25 has been considered as an exclusionary criterion for administration of alteplase. However mounting evidence has shown the benefits of intravenous thrombolysis, despite high NIHSS[1,8]. The occurrence of stroke while in the hospital allowed us to institute treatment within one hour, a factor that could have contributed to the dramatic recovery in our patient[9,10]. Prior antiplatelet therapy is not considered a contraindication for stroke thrombolysis. While thrombolysis has been reported in patients on aspirin or clopidogrel or both, this is the first report of thrombolysis in a patient on prasugrel.
In conclusion, stroke thrombolysis has to be considered on a case-to-case basis after careful consideration of the risks-to-benefits ratio and must be pursued where benefits outweigh the risks.
All the authors were part of the treating team. The manuscript was prepared by the corresponding author, and later read and acknowledged by all the authors.Financial support and sponsorship
None.Conflicts of interest
There are no conflicts of interest.Patient consent
Patient consent was obtained for publishing the case report.Ethics approval
Ethics committee approval was obtained for publishing the case report.Copyright
© The Author(s) 2017.
1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, Khatri P, McMullan PW Jr, Qureshi AI, Rosenfield K, Scott PA, Summers DR, Wang DZ, Wintermark M, Yonas H; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2013;44:870-947.DOIPubMed
2. Saver JL, Fonarow GC, Smith EE, Reeves MJ, Grau-Sepulveda MV, Pan W, Olson DM, Hernandez AF, Peterson ED, Schwamm LH. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA 2013;309:2480-8.DOIPubMed
3. Demaerschalk BM, Kleindorfer DO, Adeoye OM, Demchuk AM, Fugate JE, Grotta JC, Khalessi AA, Levy EI, Palesch YY, Prabhakaran S, Saposnik G, Saver JL, Smith EE; American Heart Association Stroke Council and Council on Epidemiology and Prevention. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2016;47:581-641.DOIPubMed
4. Fugate JE, Rabinstein AA. Absolute and relative contraindications to IV rt-PA for acute ischemic stroke. Neurohospitalist 2015;5:110-21.DOIPubMedPMC
5. Lopez-Yunez AM, Bruno A, Williams LS, Yilmaz E, Zurrú C, Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke 2001;32:12-1.DOIPubMed
6. Meretoja A, Putaala J, Tatlisumak T, Atula S, Artto V, Curtze S, Häppölä O, Lindsberg PJ, Mustanoja S, Piironen K, Pitkäniemi J, Rantanen K, Sairanen T, Salonen O, Silvennoinen H, Soinne L, Strbian D, Tiainen M, Kaste M. Off-label thrombolysis is not associated with poor outcome in patients with stroke. Stroke 2010;41:1450-8.DOIPubMed
7. De Silva DA, Manzano JJ, Chang HM, Wong MC. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology 2011;76:1838-40.DOIPubMed
8. Sylaja PN, Dong W, Grotta JC, Miller MK, Tomita K, Hamilton S, Semba C, Hill MD. Safety outcomes of Alteplase among acute ischemic stroke patients with special characteristics. Neurocrit Care 2007;6:181-5.DOIPubMed
9. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified rankin scale. Stroke 2009;40:2079-4.DOIPubMedPMC
10. Emberson J, Lees KR, Lyden P, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg M, Lindley RI, Murray G, Olivot JM, Parsons M, Tilley B, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Whiteley W, del Zoppo GJ, Baigent C, Sandercock P, Hacke W; Stroke Thrombolysis Trialists' Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet 2014;384:1929-35.DOI
Meenakshi-Sundaram S, Subburamakrishnan P, Vinoth J, Madhan-Rajah SVRS, Karthik SN, Suresh P. Dramatic recovery from stroke following intravenous thrombolysis in a patient on prasugrel for recent percutaneous coronary angioplasty. Neuroimmunol Neuroinflammation 2017;4:216-218. http://dx.doi.org/10.20517/2347-8659.2016.57
Quantities of Full-Text Views Each Month
Quantities of PDF Downloads Each Month